|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Given that osimertinib is the only approved third-generation EGFR-TKI against <i>EGFR</i> activating and resistant T790M mutated non-small cell lung cancer (NSCLC), additional mutant-selective inhibitors with a higher efficacy, especially for brain metastases, with favorable toxicity profile are still needed.
|
30670498 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Expert commentary: Osimertinib is the current treatment option for T790M mutation positive NSCLC after progression to first or second-generation EGFR TKIs, with activity also on brain metastasis.
|
30079781 |
2018 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We developed experimental brain metastasis models by intraventricular injection (intraventricular injection mouse model; IVM) of HER2-positive breast cancer (MDA-MB-361-luc-BR2/BR3) or T790M-EGFR-positive lung cancer (NCI-H1975-luc) cells.
|
29321587 |
2018 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Generally, the EGFR-T790M mutation was more common in NSCLC patients with brain metastasis and those who received TKI therapy for more than 6 months.
|
30337598 |
2018 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We detected high copy numbers of epidermal growth factor receptor mutations (L858R and T790M) in the cfDNA samples from stage IV NSCLC patients who underwent stereotactic body radiation therapy to treat brain metastasis related to tyrosine kinase inhibitor (TKI) treatment failure.
|
29721209 |
2018 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Brain metastasis-free survival was also longer in the T790M-positive group or osimertinib-treated group among patients who had no brain metastasis at the time of diagnosis.
|
29858020 |
2018 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We experienced 2 NSCLC patients with the EGFR T790M mutation; a 67-year-old woman with symptomatic multiple brain metastases administered osimertinib as seventh-line chemotherapy, and a 76-year old man with an asymptomatic single brain metastasis administered osimertinib as fifth-line chemotherapy.
|
28178168 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our report demonstrates that osimertinib is able to inhibit the growth of a radiotherapy- and surgery-refractory EGFR T790M-positive brain metastasis in a patient with lung adenocarcinoma.
|
27486808 |
2016 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We performed preclinical assessments of brain penetration and activity of osimertinib (AZD9291), an oral, potent, irreversible EGFR-TKI selective for EGFRm and T790M resistance mutations, and other EGFR-TKIs in various animal models of EGFR-mutant NSCLC brain metastases.
|
27435396 |
2016 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The clinical features of EGFR T790M-mutant lung cancer were similar to those of sensitive EGFR-mutant lung cancer, except for the overrepresentation of never-smokers and brain metastasis.
|
25450875 |
2015 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
There is a possibility to detect the primary T790M mutation in brain metastases of NSCLC in EGFR-TKIs naïve patients.
|
24789720 |
2014 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Seven mutations were T790M and one was a novel D761Y mutation found in a brain metastasis.
|
17085664 |
2006 |
|
rs1057519847
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We detected high copy numbers of epidermal growth factor receptor mutations (L858R and T790M) in the cfDNA samples from stage IV NSCLC patients who underwent stereotactic body radiation therapy to treat brain metastasis related to tyrosine kinase inhibitor (TKI) treatment failure.
|
29721209 |
2018 |
|
rs1057519848
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We detected high copy numbers of epidermal growth factor receptor mutations (L858R and T790M) in the cfDNA samples from stage IV NSCLC patients who underwent stereotactic body radiation therapy to treat brain metastasis related to tyrosine kinase inhibitor (TKI) treatment failure.
|
29721209 |
2018 |
|
rs121434568
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We detected high copy numbers of epidermal growth factor receptor mutations (L858R and T790M) in the cfDNA samples from stage IV NSCLC patients who underwent stereotactic body radiation therapy to treat brain metastasis related to tyrosine kinase inhibitor (TKI) treatment failure.
|
29721209 |
2018 |
|
rs1057519847
|
|
|
0.050 |
GeneticVariation |
BEFREE |
<b>Conclusions:</b> NSCLC patients harboring exon 19 deletion achieved better PFS and OS than those with L858R mutation, indicating that EGFR mutation is a significant prognostic factor for advanced NSCLC patients with and without brain metastasis receiving second-line EGFR-TKIs treatment.
|
28367239 |
2017 |
|
rs1057519848
|
|
|
0.050 |
GeneticVariation |
BEFREE |
<b>Conclusions:</b> NSCLC patients harboring exon 19 deletion achieved better PFS and OS than those with L858R mutation, indicating that EGFR mutation is a significant prognostic factor for advanced NSCLC patients with and without brain metastasis receiving second-line EGFR-TKIs treatment.
|
28367239 |
2017 |
|
rs121434568
|
|
|
0.050 |
GeneticVariation |
BEFREE |
<b>Conclusions:</b> NSCLC patients harboring exon 19 deletion achieved better PFS and OS than those with L858R mutation, indicating that EGFR mutation is a significant prognostic factor for advanced NSCLC patients with and without brain metastasis receiving second-line EGFR-TKIs treatment.
|
28367239 |
2017 |
|
rs1057519847
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Among EGFR-positive patients, the incidence of brain metastases was significantly higher in L858R cohort than in Del Ex19 cohort.
|
27402797 |
2016 |
|
rs1057519847
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The posterior fossa, the anatomic "watershed areas," and the gray-white matter junction were confirmed to be more commonly affected by lung cancer brain metastases, and brain metastases with epidermal growth factor receptor (EGFR) L858R mutation occurred more often in the caudate, cerebellum, and temporal lobe than those with exon 19 deletion of EGFR.
|
26519739 |
2016 |
|
rs1057519848
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The posterior fossa, the anatomic "watershed areas," and the gray-white matter junction were confirmed to be more commonly affected by lung cancer brain metastases, and brain metastases with epidermal growth factor receptor (EGFR) L858R mutation occurred more often in the caudate, cerebellum, and temporal lobe than those with exon 19 deletion of EGFR.
|
26519739 |
2016 |
|
rs1057519848
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Among EGFR-positive patients, the incidence of brain metastases was significantly higher in L858R cohort than in Del Ex19 cohort.
|
27402797 |
2016 |
|
rs121434568
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Among EGFR-positive patients, the incidence of brain metastases was significantly higher in L858R cohort than in Del Ex19 cohort.
|
27402797 |
2016 |
|
rs121434568
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The posterior fossa, the anatomic "watershed areas," and the gray-white matter junction were confirmed to be more commonly affected by lung cancer brain metastases, and brain metastases with epidermal growth factor receptor (EGFR) L858R mutation occurred more often in the caudate, cerebellum, and temporal lobe than those with exon 19 deletion of EGFR.
|
26519739 |
2016 |
|
rs1057519847
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Among the 93 patients with BM, 41 (44%) had mutations in EGFR, including 13 exon 19 deletions and 12 L858R mutations.
|
20627894 |
2010 |